Sustained release of a GLP-1 and FGF21 dual agonist from an injectable depot protects mice from obesity and hyperglycemia

There is great interest in identifying a glucagon-like peptide-1 (GLP-1)–based combination therapy that will more effectively promote weight loss in patients with type 2 diabetes. Fibroblast growth factor 21 (FGF21) is a compelling yet previously unexplored drug candidate to combine with GLP-1 due t...

Descripción completa

Detalles Bibliográficos
Autores principales: Gilroy, C. A., Capozzi, M. E., Varanko, A. K., Tong, J., D'Alessio, D. A., Campbell, J. E., Chilkoti, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449677/
https://www.ncbi.nlm.nih.gov/pubmed/32923621
http://dx.doi.org/10.1126/sciadv.aaz9890

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449677/
https://www.ncbi.nlm.nih.gov/pubmed/32923621
http://dx.doi.org/10.1126/sciadv.aaz9890

Ejemplares similares